113136-79-1

Basic information

• Product Name: Cyclopropanecarboxylic acid, 1-[[(4-chlorophenyl)amino]carbonyl]-
• CAS NO: 113136-79-1
• Molecular Formula: C11H10ClNO3
• Molecular Weight: 239.658
• Mol File: 113136-79-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxylic acid, 1-[[(4-chlorophenyl)amino]carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid, 1-[[(4-chlorophenyl)amino]carbonyl]-(113136-79-1)
• EPA Substance Registry System: Cyclopropanecarboxylic acid, 1-[[(4-chlorophenyl)amino]carbonyl]-(113136-79-1)

Safety Data

• Hazardous Substances Data: 113136-79-1(Hazardous Substances Data)

Upstream product

• 1373611-16-5 methyl 1-[(4-chlorophenyl)carbamoyl]cyclopropane-1-carboxylate 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 106-47-8 4-chloro-aniline 
• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 

Downstream Products

• 1584219-75-9 N-(4-((2-((3-((methylsulfonyl)methyl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-N'-(4-chlorophenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi

Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and cellular activity

Both c-Met and VEGFR-2 are important targets for cancer therapies. Here we report a series of potent dual c-Met and VEGFR-2 inhibitors bearing an anilinopyrimidine scaffold. Two novel synthetic protocols were employed for rapid analoguing of the designed